Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.34 |
| ▸ | EGFR | P00533 | 1/20 | 0.32 |
| ▸ | RXRA | P19793 | 4/20 | 0.32 |
| ▸ | PPARG | P37231 | 4/20 | 0.32 |
| ▸ | RARG | P13631 | 3/20 | 0.31 |
| ▸ | ELANE | P08246 | 1/20 | 0.30 |
| ▸ | CD69 | Q07108 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23014691 | 0.90 | ALDH1A1 (0.44) | ALDH1A1CYP1A2CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL28734927 | 0.83 | CA2 (0.46) | ALDH1A1CYP1A2CYP2C9CYP2C19EGFR | |
| SCHEMBL5086986 | 0.83 | CYP2D6 (0.38) | ALDH1A1CYP1A2CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL6605780 | 0.83 | RXRA (0.42) | ALDH1A1CYP1A2CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL29498841 | 0.83 | RXRA (0.42) | ALDH1A1CYP1A2CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL28734957 | 0.82 | HTR2A (0.30) | — | |
| SCHEMBL1229433 | 0.81 | CYP2C19 (0.39) | ALDH1A1CYP1A2CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL3770921 | 0.80 | CA2 (0.42) | ALDH1A1CYP1A2CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL29163256 | 0.80 | EGFR (0.37) | EGFRRXRAPPARGRARGELANE | |
| SCHEMBL4853420 | 0.80 | RXRA (0.44) | ALDH1A1CYP1A2CYP2D6CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113423744-B | Lewis base catalyst and method thereof | 埃克森美孚化学专利公司 | 2023-05-05 | — | — | CN | disclosed |
| US-11248070-B2 | Lewis base catalysts and methods thereof | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2022-02-15 | — | — | US | disclosed |
| CN-113423744-A | Lewis base catalyst and process therefor | 埃克森美孚化学专利公司 | 2021-09-21 | — | — | CN | disclosed |
| US-20200255556-A1 | Lewis Base Catalysts and Methods Thereof | EXXONMOBIL CHEMICAL PATENTS INC. | 2020-08-13 | — | — | US | disclosed |
| US-7915455-B2 | Transition metal complex ligand and olefin polymerization catalyst containing transition metal complex | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2011-03-29 | — | — | US | disclosed |
| US-7915455-B2 | Transition metal complex ligand and olefin polymerization catalyst containing transition metal complex | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2011-03-29 | — | — | US | disclosed |
| US-20090143620-A1 | Transition metal complex ligand and olefin polymerization catalyst containing transition metal complex | SUMITOMO CHEMICAL COMPANY, LIMITED | 2009-06-04 | — | — | US | disclosed |
| US-7482414-B2 | Transition metal complex ligand and olefin polymerization catalyst containing transition metal complex | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2009-01-27 | — | — | US | disclosed |
| US-7482414-B2 | Transition metal complex ligand and olefin polymerization catalyst containing transition metal complex | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2009-01-27 | — | — | US | disclosed |
| US-20070135600-A1 | Transition metal complex ligand and olefin polymerization catalyst containing transition metal complex | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2007-06-14 | — | — | US | disclosed |
| US-6320047-B1 | ACYL- OR THIOACYL-AMINOPYRIDINES | ALLERGAN SALES, INC. | 2001-11-20 | — | — | US | disclosed |
| US-6245786-B1 | ANTIPROLIFERATIVE AGENTS; SKIN DISORDERS | ALLERGAN SALES, INC. | 2001-06-12 | — | — | US | disclosed |
| US-6103762-A | A BIAROMATIC COMPOUNDS IN WHICH THE AROMATIC NUCLEI ARE CONNECTED BY A PROPYNYLENE OR ALLENYLENE DIVALENT RADICAL, USEFUL AS HUMAN OR VETERINARY MEDICINE OR USED IN COSMETICS OR KERATINIZATION DISORDERS | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2000-08-15 | — | — | US | disclosed |
| US-6051713-A | USEFUL AS REGULATORS OF CELL PROLIFERATION AND DIFFERENTIATION, PARTICULARLY AS AGENTS FOR TREATING SKIN RELATED DISEASES, INCLUDING ACTINIC KERATOSES, ARSENIC KERATOSES, INFLAMMATORY AND NON-KERATINIZATION SKIN DISORDERS | ALLERGAN SALES, INC. (US) | 2000-04-18 | — | — | US | disclosed |
| EP-0986537-A2 | NOVEL HETEROETHYNYLENE COMPOUNDS AND PHARMACEUTICAL AND COSMETIC COMPOSITIONS CONTAINING SAME | Galderma Research & Development, S.N.C. (FR) | 2000-03-22 | — | — | EP | disclosed |
| US-5965606-A | RETINOID RECEPTORS, 2-FLUORO-4-(2',2',4',4'-TETRAMETHYL-8'-TRIFLUOROMETHYLCHROMAN-6' -YL)CARBAMOYL BENZOIC ACID FOR TREATING MONOCYTIC LEUKEMIA | ALLERGAN SALES, INC. (US) | 1999-10-12 | — | — | US | disclosed |
| WO-1999050239-A2 | NOVEL HETEROETHYNYLENE COMPOUNDS AND PHARMACEUTICAL AND COSMETIC COMPOSITIONS CONTAINING SAME | GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) | 1999-10-07 | — | — | WO | disclosed |
| US-5917048-A | Substituted aryl or heteroarylamides having retinoid-like biological activity | ALLERGAN SALES INC. (US) | 1999-06-29 | — | — | US | disclosed |
| CN-1207727-A | Substd. aryl or heteroarylamides having retinoid-like biological activity | VISION PHARM LP (US) | 1999-02-10 | — | — | CN | disclosed |
| US-5663357-A | COMPOUNDS FOR TREATMENT OF SKIN DISORDERS | ALLERGAN (US) | 1997-09-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070135600-A1 | Transition metal complex ligand and olefin polymerization catalyst containing transition metal complex | AP1M1, OR10J3, AP2M1 | ALDH1A1 4017/4885CYP1A2 2917/4885CYP2D6 2096/4885 |
| US-20090143620-A1 | Transition metal complex ligand and olefin polymerization catalyst containing transition metal complex | AP1M1, OR10J3, AP2M1 | ALDH1A1 4017/4885CYP1A2 2917/4885CYP2D6 2096/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.